Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Walsh

Showing results (1161-1170 of 1,300) with videos related to

Pageof 130
Sort By:
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitorsEdward J Brnardic, Robert M Garbaccio, Mark E Fraley, et al.
Annals of Clinical and Translational Neurology|December 5, 2019
Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1Jonathan M Payne, Stephen J C Hearps, Karin S Walsh, et al.
Surgical Oncology|January 22, 2026
The rate of non-sentinel lymph node metastases at axillary dissection in patients with a positive sentinel lymph node after neoadjuvant chemotherapyA M Zaborowski, F Wehrmann, J McGarry, et al.
Transfusion Medicine Reviews|May 28, 2013
Restrictive vs liberal blood transfusion for acute upper gastrointestinal bleeding: rationale and protocol for a cluster randomized feasibility trialVipul Jairath, Brennan C Kahan, Alasdair Gray, et al.
Bioorganic & Medicinal Chemistry Letters|July 19, 2001
Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferaseD C Beshore, I M Bell, C J Dinsmore, et al.
Journal of Medicinal Chemistry|August 25, 2001
Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potencyI M Bell, S N Gallicchio, M Abrams, et al.
Health Technology Assessment (Winchester, England)|July 1, 2026
Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluationTimothy S Walsh, Richard A Parker, Leanne M Aitken, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSPRobert M Garbaccio, Edward S Tasber, Lou Anne Neilson, et al.
Journal of Medicinal Chemistry|June 27, 2008
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancerChristopher D Cox, Paul J Coleman, Michael J Breslin, et al.
Journal of Medicinal Chemistry|May 30, 2003
Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeysEric E Boros, Vicente Samano, John A Ray, et al.
Pageof 130

Showing results (1161-1170 of 1,300) with videos related to

Sort By:
Pageof 130
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitorsEdward J Brnardic, Robert M Garbaccio, Mark E Fraley, et al.
Annals of Clinical and Translational Neurology|December 5, 2019
Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1Jonathan M Payne, Stephen J C Hearps, Karin S Walsh, et al.
Surgical Oncology|January 22, 2026
The rate of non-sentinel lymph node metastases at axillary dissection in patients with a positive sentinel lymph node after neoadjuvant chemotherapyA M Zaborowski, F Wehrmann, J McGarry, et al.
Transfusion Medicine Reviews|May 28, 2013
Restrictive vs liberal blood transfusion for acute upper gastrointestinal bleeding: rationale and protocol for a cluster randomized feasibility trialVipul Jairath, Brennan C Kahan, Alasdair Gray, et al.
Bioorganic & Medicinal Chemistry Letters|July 19, 2001
Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferaseD C Beshore, I M Bell, C J Dinsmore, et al.
Journal of Medicinal Chemistry|August 25, 2001
Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potencyI M Bell, S N Gallicchio, M Abrams, et al.
Health Technology Assessment (Winchester, England)|July 1, 2026
Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluationTimothy S Walsh, Richard A Parker, Leanne M Aitken, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSPRobert M Garbaccio, Edward S Tasber, Lou Anne Neilson, et al.
Journal of Medicinal Chemistry|June 27, 2008
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancerChristopher D Cox, Paul J Coleman, Michael J Breslin, et al.
Journal of Medicinal Chemistry|May 30, 2003
Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeysEric E Boros, Vicente Samano, John A Ray, et al.
Pageof 130